Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Times Interest Earned (2019 - 2022)

Keros Therapeutics' Times Interest Earned history spans 4 years, with the latest figure at -$24126.0 for Q1 2022.

  • For Q1 2022, Times Interest Earned fell 53.0% year-over-year to -$24126.0; the TTM value through Dec 2022 reached -$114790.0, down 714.5%, while the annual FY2022 figure was -$114790.0, 714.5% down from the prior year.
  • Times Interest Earned reached -$24126.0 in Q1 2022 per KROS's latest filing, down from -$4866.0 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$775.33 in Q3 2019 to a low of -$24126.0 in Q1 2022.
  • Average Times Interest Earned over 4 years is -$9955.0, with a median of -$8444.0 recorded in 2020.
  • Peak YoY movement for Times Interest Earned: tumbled 723.39% in 2020, then soared 63.39% in 2021.
  • A 4-year view of Times Interest Earned shows it stood at -$775.33 in 2019, then crashed by 1614.23% to -$13291.0 in 2020, then skyrocketed by 63.39% to -$4866.0 in 2021, then plummeted by 395.81% to -$24126.0 in 2022.
  • Per Business Quant, the three most recent readings for KROS's Times Interest Earned are -$24126.0 (Q1 2022), -$4866.0 (Q4 2021), and -$20197.0 (Q3 2021).